

March 27, 2026

Subject: Invitation to the 2026 Annual General Meeting of Shareholders through the format of electronic media (e-AGM) only.

To: Shareholders of Aesthetic Connect Public Company Limited

Enclosures:

1. Form 56-1 One Report for the year 2025 and Financial Statements for the year ended 31 December 2025 of the Company which have been audited by a certified public accountant (in QR Code)
2. Definition of Independent Directors and Profiles of Nominated Candidates for Re-election as Directors
3. Information of the Proposed Auditors for 2026
4. Proxy Form A (General and Simple Form), Proxy Form B (Form with fixed and specific details for authorizing proxy) and Proxy Form C (For foreign investors appointed custodian in Thailand)
5. Profiles of Independent Director Designated as Proxy
6. Extracted Articles of Association of the Company in relation to the Shareholders' Meeting
7. Registration Process for Attending e-Shareholder Meeting / Documents for Identity Verification in the Registration Process / Method of Attendance / Voting and Vote Counting
8. Manual for using The Electronic Annual General Meeting (for Shareholder)
9. Registration Form for Authorized Signatory of Juristic Person, Administrator of the Estate and Guardian Curator of the Shareholder
10. Contact Channel for more Information

Aesthetic Connect Public Company Limited (the "**Company**") wishes to inform you that the Board of Directors passed the resolution to call the holding of the 2026 Annual General Meeting of Shareholders on **Wednesday, 29 April 2026, at 14.00 hours**, which will be held through the format of electronic media (e-AGM) only. The e-Shareholder Meeting will be proceeded according to the law governing electronic meetings, under the virtual meeting room named "**Annual General Meeting 2026 - Aesthetic Connect Public Company Limited**". The meeting shall be held to consider the following agendas:

Agenda 1 To acknowledge the result of the Company's operations for the year 2025

Purpose and Rationale:

The Company has summarized the performance as well as significant changes in 2025. The details are presented in the Annual Report (Form 56-1 One Report) for the year 2025, Part 1: Business Operations and Performance, in the form of a QR Code, which has been delivered to shareholders together with this meeting invitation, as shown in Enclosure 1.

The Board of Director's Opinion:

The Board of Directors deems it appropriate to propose that the Annual General Meeting of Shareholders for the year 2026 acknowledge the Company's operating results for the year 2025, as detailed in the Annual Report (Form 56-1 One Report) 2025, Part 1: Business Operations and Performance, which is provided in QR Code.

Passing Resolution:

This agenda is for acknowledgement and does not require voting.

Agenda 2 To acknowledge the change in objectives of utilization of proceeds obtained from the Initial Public Offering (IPO).

Purpose and Rationale:

As the Company has conducted its initial public offering (IPO) of 90 million newly issued ordinary shares, with a par value of Baht 0.50 per share, at an offering price of Baht 14.00 per share, totaling Baht 1,260.00 million, the net proceeds after deducting offering expenses amounted to Baht 1,215.28 million, in accordance with the objectives and details specified in the Company's prospectus.

Subsequently, the Board of Directors' Meeting No. 4/2025, held on 7 November 2025, resolved to approve an extension of the utilization period of the IPO proceeds. In addition, the Board of Directors' Meeting No. 1/2026, held on 27 February 2026, resolved to approve a change in the objectives of the use of proceeds from the IPO by reallocating funds among the previously disclosed items in the prospectus. Specifically, Baht 30 million was reallocated from Objective No. 2 (Purchasing medical tools and equipment) to Objective No.1 (Invest in hospital construction projects).

Such change is considered immaterial in accordance with the notification of the Office of the Securities and Exchange Commission No. SorJor. 63/2561 regarding changes in the use of proceeds as disclosed in the registration statement and draft prospectus. The Company has already disclosed the details of such changes through the Stock Exchange of Thailand's disclosure system.

Details of the extension of the utilization period and the reallocation of IPO proceeds are presented in the table below:

| The purpose of the use of fund               | <u>Before the change</u>                           |                                                               |                                    | <u>After the change</u>                            |                                                               |                                    |
|----------------------------------------------|----------------------------------------------------|---------------------------------------------------------------|------------------------------------|----------------------------------------------------|---------------------------------------------------------------|------------------------------------|
|                                              | Plan of the estimated spending based on Prospectus | Detail                                                        | The period of expected use of fund | Plan of the estimated spending based on Prospectus | Detail                                                        | The period of expected use of fund |
|                                              | (Million Baht))                                    |                                                               |                                    | (Million Baht)                                     |                                                               |                                    |
| 1. Invest in hospital construction projects. | <u>550</u>                                         | Construction hospital 5 floor building                        | <u>In 2025</u>                     | <u>580</u>                                         | Construction hospital 5 floor building                        | <u>In 2026</u>                     |
| 2. Purchasing medical tools and equipment    | <u>80</u>                                          | Purchasing medical equipment                                  | <u>In 2025</u>                     | <u>50</u>                                          | Purchasing medical equipment                                  | <u>In 2026</u>                     |
| 3. Repay loans from financial institutions.  | 95.44                                              | for repaying loans from financial institutions of the company | In 2023                            | 95.44                                              | for repaying loans from financial institutions of the company | In 2023                            |
| 4. To use as working capital for business    | 489.84                                             | The company will consider the use of working capital          | -                                  | 489.84                                             | The company will consider the use of working capital          | -                                  |

|                                                                               |                 |                                                                                                                                        |  |                 |                                                                                                                                        |  |
|-------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|--|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|--|
| operations other investment and expansion of the company's business ( if any) |                 | in the business depending on the need for money at a particular time for the benefit of managing the liquidity of business operations. |  |                 | in the business depending on the need for money at a particular time for the benefit of managing the liquidity of business operations. |  |
| <b>Total</b>                                                                  | <b>1,215.28</b> |                                                                                                                                        |  | <b>1,215.28</b> |                                                                                                                                        |  |

The Board of Director's Opinion:

The Board of Directors has considered and deemed it appropriate to propose that the Annual General Meeting of Shareholders for the year 2026 acknowledge the changes in the utilization period and the changes in the objectives for the use of proceeds from the initial public offering (IPO), as detailed below:

**(1) Amount or utilization period to be changed**

The Company has extended the utilization period for Objectives No. 1 and No. 2 from within 2025 to within 2026. In addition, the Company has made a change in the objectives for the use of IPO proceeds, which is considered immaterial, by reallocating approximately Baht 30 million from Objective No. 2, "procurement of medical tools and equipment," to Objective No. 1, "investment in the hospital construction project." This represents a reallocation of funds among items already disclosed in the registration statement and prospectus.

**(2) Rationale, necessity, and benefits to shareholders**

The change is reasonable, aligned with current circumstances, and beneficial and worthwhile for both the Company and its shareholders. It enhances operational efficiency in line with the Company's business plan. The reallocation of funds to the hospital construction project will enable the Company to achieve its intended objectives and optimize the utilization of its financial resources.

**(3) Summary of changes in investment budget or expenses**

Details are presented in the table summarizing the changes in the utilization period and the reallocation of IPO proceeds, as described above.

**(4) Plan for utilization of proceeds after the change**

The Company has a plan to reallocate funds for investment in the construction of a five-story hospital building, with the intention to utilize such funds in accordance with the stated objective within the year 2026.

**(5) Expected impact on the Company's operations or disclosed projections**

The change in the use of proceeds has no impact on the Company's business operations or on any projections disclosed in the registration statement.

Passing Resolution:

This agenda is for acknowledgement and does not require voting.

Agenda 3 To consider and approve the Company's Financial Statements for the fiscal year ended December 31,2025 which have been audited by the certified public accountant.

Purpose and Rationale:

In order to comply with Section 112 of the Public Limited Companies Act B.E. 2535 (including amendments) ("Public Company Act") and Article 49 of the Company's Articles of Association, which stipulates that "The Board of Directors must prepare an accurate and complete balance sheet and profit and loss statement as of the end of the Company's fiscal year to be presented to the shareholders at the Annual General Meeting for approval. The Board of Directors must also arrange for the financial statements to be audited by a certified public accountant before presenting them to the shareholders' meeting."

Therefore, it was considered appropriate to propose this to the shareholder's meeting to consider and approve the Company's financial statements for the year 2025 ending on December 31, 2025, which have been considered by the Company's Audit Committee and have been audited by a certified public accountant. The main details are summarized as follows.

Unit: Million Baht

| Description                     | 2025     | 2024     |
|---------------------------------|----------|----------|
| Total Assets                    | 1,727.44 | 1,871.79 |
| Total Liabilities               | 107.49   | 150.54   |
| Total Shareholder's Equity      | 1,619.95 | 1,721.25 |
| Total revenues                  | 481.58   | 554.74   |
| Net Profit for the year         | 87.20    | 139.37   |
| Earnings Per Share (Baht:Share) | 0.25     | 0.40     |

Other details appear in the copy of the company's financial statements for the year 2025, ending on December 31, 2025 (Enclosure 1)

The Board of Director's Opinion:

The Board of Directors deems it appropriate to propose that the shareholders' meeting consider and approve the Company's financial statements for the year 2025, ended 31 December 2025, which have been reviewed by the Audit Committee and audited by a certified public accountant, as detailed above. The opinions of the Board of Directors and the Audit Committee are set out in the Report of the Board of Directors' Responsibility for Financial Statements and the Audit Committee Report, as disclosed in the Annual Report (Form 56-1 One Report) 2025, Part 3 under the section "Report of the Board of Directors' Responsibility for Financial Statements," in QR Code.

Passing Resolution:

Resolution of this agenda shall be passed by a majority of the total number of votes of the Shareholders who attend the meeting and cast their votes.

- Agenda 4 To consider and approve the allocation of the net profit as a legal reserve and dividend payment.

Purpose and Rationale:

The company has a policy to pay dividends in the amount of not less than 50 percent of the net profits after the deduction of the corporate income tax and legal reserve funds each year (if any). The company will consider paying dividends by taking into account various factors. In order to provide maximum benefits to the shareholders, the payment of dividends must not have a significant impact on the normal operations of the company. However, such dividend payment is subject to change depending on operating results and financial status, liquidity, business expansion plans, necessity and suitability in the

future and other factors. involved in the management of the company according to the appropriate opinion of the Board of Directors.

The company had a net profit of 87,199,538.63 baht the year 2025, proposed to the meeting to consider paying cash dividends for the company's operating results for the year 2025 at the rate of 0.25 baht per share, equivalent to a total value of 82,448,300 baht. All dividends will be subject to withholding tax at the rate specified by law. The Company will pay such dividends to shareholders according to the names that appear on the record date for determining the names of shareholders with the rights to receive dividends (Record Date) on May 12, 2026, and will pay dividends to shareholders on May 27, 2026.

Comparative information on dividend payments

| Details of Dividend Payment                    | Year 2025<br>(Proposing Year) | Year 2024      |
|------------------------------------------------|-------------------------------|----------------|
| Net Profit for the year (Million Baht)         | 87,199,538.63                 | 139,367,751.47 |
| Legal Reserve (Million Baht)                   | -                             | -              |
| Net Profit for Dividend Payment (Million Baht) | 87,199,538.63                 | 139,367,751.47 |
| Number of shares (Million shares)              | 350,000,000                   | 350,000,000    |
| Treasury shares (shares)                       | 20,206,800                    | -              |
| Net outstanding shares (shares)                | 329,793,200                   | 350,000,000    |
| Cash dividend                                  | Year 2025<br>(Proposing Year) | Year 2024      |
| Interim cash dividend (million baht)           | -                             | -              |
| Final cash dividend (million baht)             | 82,448,300                    | 70,000,000     |
| Total dividend paid per year (million baht)    | 82,448,300                    | 70,000,000     |
| Dividend payment per share (baht:share)        | 0.25                          | 0.20           |
| Dividend Payout Ratio                          | 94.55%                        | 50.23%         |

The Board of Director's Opinion:

The Board of Directors deems it appropriate to propose to the Shareholders' Meeting for consideration and approval of the payment of cash dividends for the Company's operating results for the year 2025 at the rate of 0.25 baht per share, with a total value of 82,448,300 baht, representing 94.55% of the net profit according to the financial statements. This is in accordance with the Company's dividend payment policy. The dividends will be paid to shareholders whose names appear on the Record Date, set for May 12, 2026, with the dividend payment scheduled for May 27, 2026. However, the dividend payment remains uncertain as it is subject to approval by the Shareholders' Meeting.

Currently, the Company has accumulated legal reserves totaling 17.5 million baht, which meets the 10% requirement of the registered capital. Therefore, no additional legal reserve allocation is required.

Passing Resolution:

Resolution of this agenda shall be passed by a majority of the total number of votes of the shareholders who attend the meeting and cast their votes.

Agenda 5 To consider and approve the appointment of directors in replacement of those who must retire by rotation.

Purpose and Rationale:

Section 71 of the PLCA and Article 22 of the Articles of Association of the Company stipulate that “At every annual general meeting of shareholders, one-third of the total number of directors must retire by rotation. If the number of directors cannot be divided into three, the closest number to one-third shall retire. The retired directors are eligible for re-election. After the registration of the Company, the retiring directors in the first and second year shall conduct a draw on whether who shall be retiring. In the later year, the directors who have the longest staying period shall retire from the position.”

The Company has a total of 9 directors. At the 2026 Annual General Meeting of Shareholders, 3 directors are due to retire by rotation, namely:

- |                                |                                                                                                                              |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| 1. Mr. Tanachak Sinrachatanant | Director / Executive Director                                                                                                |
| 2. Mrs.Sunisa Thaichinda       | Director                                                                                                                     |
| 3. Mr. Kirkchai Chaiyatham     | Director / Independent Director/ Audit Committee<br>Nomination and Remuneration Committee/ Corporate<br>Governance Committee |

The Board of Directors excluding interested directors (as approved by the Nomination and Remuneration Committee) has considered history, qualifications, experience, expertise, and suitability including the performance of directors who have left their positions after their terms have expired. It is seen that the directors nominated this time have gone through the screening process. The Board of Directors has carefully considered that they have all the qualifications and are suitable for the Company's business operations, with knowledge, abilities, specialized expertise, experience, vision, and reliability, and does not have prohibited characteristics as specified by law. Those who hold the position of independent director have the qualifications of independent director according to the requirements of the Securities and Exchange Commission and is suitable to hold the position of independent director of the company. (Details according to Enclosure 2) Therefore, the Board of Directors deems it appropriate to propose to the 2026 Annual General Meeting of Shareholders for consideration and approval of the reappointment of these three directors for another term.

In addition, the Company invited shareholders to nominate qualified candidates for directorship through the Company's website from November 10,2025 to December 31,2025. Despite the invitation, no candidates were proposed.

The Board of Director's Opinion:

The Board of Directors (according to the approval of the Nomination and Remuneration Committee) has considered and is of the opinion that the three nominated directors possess the qualifications in accordance with relevant regulations and are suitable for the Company's business operations. Additionally, the nominated independent directors meet the legal requirements and qualifications for independent directorship. Therefore, it is deemed appropriate to propose to the Shareholders' Meeting for consideration and approval of the election of the three directors who are due to retire by rotation, namely: (1) Mr. Tanachak Sinrachatanant (2) Mrs.Sunisa Thaichinda and (3) Mr. Kirkchai Chaiyatham return to serve as directors of the company for another term according to the details presented above in all respects.

Passing Resolution:

Resolution of this agenda shall be passed by a majority of the total number of votes of the Shareholders who attend the meeting and cast their votes. The resolution of this agenda shall be made for each director on an individual basis.

- Agenda 6 To consider and approve the directors' remuneration and the remuneration for the sub-committee member for the year 2026.

Purpose and Rationale:

According to Section 90 of the Public Company Act and the Company's Articles of Association, Article 35, directors are entitled to receive director's remuneration from the Company in accordance with the Company's regulations or as determined by the shareholder meeting and pass a resolution with a vote of not less than two-thirds of the total number of votes of shareholders present at the meeting. The remuneration of directors may be set at a fixed amount or laid down according to specific criteria. This may be specified from time to time or effective until the shareholder meeting resolves to change otherwise.

The Board of Directors has considered and established a policy for the remuneration of company directors and sub-committees in a fair and reasonable manner in accordance with the principles of good corporate governance. The Nomination and Remuneration Committee has been assigned the responsibility of determining compensation that is appropriate and consistent with the strategic long term goals, the Company performance and assigned duties and responsibilities by comparing with companies listed on the stock exchange in the same industry group and companies of similar sizes to set remuneration at an appropriate and sufficient levels to attract and retain quality directors.

In this regard, the Board of Directors' meeting jointly considered the remuneration structure for the Company's directors and sub-committees as proposed by the Nomination and Remuneration Committee. It is seen that the compensation structure for company directors This will help to support and promote the performance of the duties of the Board of Directors. Therefore, it was proposed that the meeting considers and approves the determination of directors' remuneration and remuneration for sub-committees for the year 2026 (as approved by the Nomination and Remuneration Committee), with details of remuneration compared to 2025 as follows:

**Year 2026 (Proposing Year)**

| Directors                                            | Monthly Remuneration (Baht/month) | Meeting Allowance (Baht/time)        | Directors' gratuity, (Bath/person/year) |
|------------------------------------------------------|-----------------------------------|--------------------------------------|-----------------------------------------|
| Chairman of the Board                                | 30,000                            | 10,000                               | 200,000                                 |
| Independent Directors                                | 25,000                            | 8,000                                | 200,000                                 |
| Directors                                            | -                                 | 8,000                                | -                                       |
| <b>sub-committees for Independent Directors only</b> |                                   | <b>Meeting Allowance (Baht/time)</b> |                                         |
| Chairman                                             |                                   | 10,000                               |                                         |
| Directors                                            |                                   | 8,000                                |                                         |
| <b>Other benefits</b>                                | -None-                            |                                      |                                         |

Year 2025

| Directors                                     | Monthly Remuneration (Baht/month) | Meeting Allowance (Baht/time) | Directors' gratuity, (Bath/person/year) |
|-----------------------------------------------|-----------------------------------|-------------------------------|-----------------------------------------|
| Chairman of the Board                         | 30,000                            | 10,000                        | 200,000                                 |
| Independent Directors                         | 25,000                            | 8,000                         | 200,000                                 |
| Directors                                     | -                                 | 8,000                         | -                                       |
| sub-committees for Independent Directors only |                                   | Meeting Allowance (Baht/time) |                                         |
| Chairman                                      |                                   | 10,000                        |                                         |
| Directors                                     |                                   | 8,000                         |                                         |
| <b>Other benefits</b>                         | -None-                            |                               |                                         |

The Board of Director's Opinion:

The Board of Directors deems it appropriate to propose to the shareholders' meeting to consider and approve the remuneration of the Company's directors and the remuneration of sub-committees for the year 2026. The remuneration is categorized into salary, meeting allowance, directors' gratuity, and other benefits as detailed above in all respects.

The determination of such remuneration for the directors has been reviewed and screened by the Nomination and Remuneration Committee

Passing Resolution:

Resolution of this agenda shall be passed by an affirmation vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting.

Agenda 7 To consider and approve the appointment of auditors and to determine auditors' remuneration for the year 2026

Purpose and Rationale:

In order to comply with Section 120 of the Public Company Act and Article 51 of the Company's Regulations, which requires that the annual general meeting appoint the company's auditor and determine the audit fee for the auditor, and that an auditor who has vacated their position has the right to be re-elected, the Audit Committee has reviewed and proposed the selection of auditors. After consideration by the Board of Directors, it is proposed that the Shareholders' Meeting approve the appointment of auditors from Office of Pitisevi Company Limited, who are certified by the Securities and Exchange Commission, as the Company's auditors for the year 2026 (for the accounting period from January 1, 2026, to December 31, 2026), comprising a total of four auditors as follows:

1. Ms.Chaovana Viwatpanachati Certified Public Accountant (Thailand) No. 4712 or
2. Ms.Wanpen Unruan Certified Public Accountant (Thailand) No. 7750 or
3. Ms.Porntip Amornchailertpattana Certified Public Accountant (Thailand) No. 9589 or
4. Ms.Nuntira Kunngam Certified Public Accountant (Thailand) No. 12707 or
5. Mr.Mongkon Laoworapong Certified Public Accountant (Thailand) No. 4722

In this regard, any one of the above-mentioned auditors shall be responsible for auditing, reviewing, and providing auditor's opinion to the Company's financial statements. All four certified auditors are not shareholders of the Company, have no relationship with the Company, and have no conflicts of interest with the Company, its management, major shareholders, or any related persons. Additionally, they do not provide any advisory services to the Company, ensuring their independence in auditing and expressing opinions on the Company's financial statements. Details of the nominated auditors' profiles are provided in Enclosure 3.

In the event that the above-named auditors are unable to perform their duties, Office of Pitisevi Company Limited shall provide another certified auditor from the same firm as a replacement.

The auditor's remuneration for the year 2026 (as approved by the Audit Committee) is determined as follows:

1. The annual audit fees of 420,000 Baht and quarterly review fees for 3 Quarters and the rate of 150,000 Baht per quarter. Total audit fee for the year 2024 equals to 870,000 Baht.
2. Allowances for auditing staff working Observe the inventory count on public holidays as follows. Allowances for senior level officials are 400 baht per person per day. Allowances for assistant level officials are 300 baht per person per day.
3. Other related expenses actual charge.
4. The Company shall be responsible for arranging and providing appropriate accommodation for employees when they are assigned to work at the Company's office in other provinces.
5. Expenses for observing product destruction are 5,000 baht per time. (If any)

Comparison of audit fees for the current and previous year.

| Auditor's Remuneration | 2026 (Proposing Year) | 2025         |
|------------------------|-----------------------|--------------|
| Quarterly review fees  | 450,000 Baht          | 450,000 Baht |
| Annual audit fees      | 420,000 Baht          | 420,000 Baht |
| Non-Audit Fee          | -None-                | -None-       |
| Total audit fee        | 870,000 Baht          | 870,000 Baht |

The Board of Director's Opinion:

The Board of Directors deemed appropriate to propose the shareholder Meeting to consider and approve the appointment of Ms.Chaovana Viwatpanachati Certified Public Accountant (Thailand) No. 4712 or Ms.Wanpen Unrun Certified Public Accountant (Thailand) No. 7750 or Ms.Porntip Amornchailert-pattana Certified Public Accountant (Thailand) No. 9589 or Ms.Nunthira Khunngam Certified Public Accountant (Thailand) No. 12707 or Mr.Mongkon Laoworappong Certified Public Accountant (Thailand) No.4722 of Office of Pitisevi Company Limited by designating one of the auditors on the list as mentioned above the person who audits and expresses opinions on the company's financial statements for the year 2026 and to approve the auditor's remuneration for the year 2026 in the amount of 870,000 Baht (excluding out-of-pocket expenses). According to the details presented above in all respects.

Passing Resolution:

Resolution of this agenda shall be passed by a majority of the total number of votes of the shareholders who attended the meeting and cast their votes.

Agenda 8 To consider other agenda (if any).

The Board of Director has no other matters to propose for the consideration of the shareholders' meeting. The Company provided an opportunity for the shareholders to propose additional agenda for the Shareholders' Meeting from November 10, 2025 to December 31, 2025, but no Shareholder proposing any additional agenda.

Schedules of the 2026 Annual General Meeting of Shareholders are as the follow:

| Descriptions                                                                                  | Date           |
|-----------------------------------------------------------------------------------------------|----------------|
| 1. Specify the name list of shareholders who are eligible to attend the Shareholders meeting. | March 18, 2026 |
| 2. Convening the 2026 Annual General Meeting of the Shareholders                              | April 29, 2026 |

Therefore, the company wishes to invite the Shareholders to attend the 2026 Annual General Meeting of Shareholders on the specified date and time which is to be held through electronic media (e-AGM) only. Shareholders can review the details of the meeting participation in Enclosure 7 and Enclosure 8. If you have any questions, please contact us via the contact channel provided in Enclosure 10. Additionally, Shareholders may register their intention to attend the meeting via the E-Request system by scanning the QR Code below. The Company will open the system for advance registration starting from Wednesday, April 1, 2026, onwards.

If any shareholder wishes to appoint another person as a proxy to attend the meeting and vote, please fill in and sign the attached proxy form. (Enclosure No.4) and deliver the proxy form before attending the meeting to Company Secretary Department, Aesthetic Connect Public Company Limited, No.549 Somdet Phra Chao Taksin Road, Samre Subdistrict, Thon Buri District, Bangkok 10600 by 20 April 2026. In addition, the Company has provided e-Proxy Voting aiming to facilitate shareholders conveniently, broaden channel to facilitate shareholders in exercising voting rights and also helps reduce paper usage and Greenhouse gases (GHG). Please access via Investor Portal (IVP) <https://ivp.tsd.co.th/> to complete information via e-Proxy Voting instead of submitting the proxy form and related documents to the Company.

Yours sincerely,

Aesthetic Connect Public Company Limited



(Prof. Dr. Apichati Sivayathorn)

Chairman of the Board

Note:

1. In the event that shareholders wish to inquire about information related to the meeting on any agenda of the company, shareholders can send questions in advance to the company by April 20, 2026 at the Company Secretary Department, Aesthetic Connect Public Company Limited.No. 549 Somdet Phra Chao Taksin Road, Samre Subdistrict, Thon Buri District, Bangkok 10600 or at [daranee.d@teerapornhospital.com](mailto:daranee.d@teerapornhospital.com).You can download the form from the website: <https://trphospital.com/information-for-shareholders/>

2. Shareholders can register their intention to attend the meeting via the E-Request system by scanning the QR Code below or accessing <https://trp.thekoble.com/agm/emeeting/index/1> The Company will open the system for advance registration starting from Wednesday, April 1, 2026, onwards.

